广东万年青制药股份有限公司（以下简称"公司"）于 2022 年 12 月 19 日召 开第二届董事会第十次会议及第二届监事会第八次会议，并于 2023 年 1 月 4 日 召开 2023 年第一次临时股东大会，审议通过了《关于使用部分闲置募集资金（含 超募资金）和自有资金进行现金管理的议案》，同意公司在确保不影响正常运营和 募集资金投资项目建设的情况下，使用不超过人民币 2.5 亿元（含 2.5 亿元）的 闲置募集资金（含超募资金）及不超过人民币 2.5 亿元（含 2.5 亿元）的自有资 金进行现金管理，上述额度自股东大会审议通过之日起 12 个月内有效。在上述额 度和期限范围内，资金可循环滚动使用。公司独立董事及保荐机构均发表了明确 同意的意见。具体内容详见公司于 2022 年 12 月 20 日及 2023 年 1 月 5 日披露于 巨潮资讯网（www.cninfo.com.cn）上的相关公告。 近期，公司使用部分闲置募集资金（含超募资金）进行现金管理已到期赎回， 并继续进行现金管理，现将相关事宜公告如下： | 序 | 受托方 | 产品名称 | 产品类型 | 购买金额 | 产品期限 | 实际年化 | 收益 ...

证券代码：301111 证券简称：粤万年青 公告编号：2023-037 针对近期出现的支原体肺炎、呼吸道感染情况，预计对公司整体经营业绩不 会造成重大影响。 2、公司当前基本面未发生重大变化，股价短期内涨幅较大，可能存在二级市 场炒作风险，公司提醒广大投资者注意二级市场交易风险，审慎决策，理性投资。 广东万年青制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、公司关注到近期出现支原体肺炎等相关市场热点，目前公司没有生产及销 售专门治疗支原体肺炎的药品。 公司旗下产品涵盖降糖类、胆道类、补益类、感冒类等多个用药领域。2023 年 1-9 月份，公司治疗感冒、咳嗽的产品合计销售收入占公司当期主营业务收入 比例约为四分之一（未经审计）。 一、 股票交易异常波动的具体情况 广东万年青制药股份有限公司（以下简称"公司"）股票（证券简称：粤万 年青，证券代码：301111）交易连续 3 个交易日内日收盘价格涨幅偏离值累计达 到 30%，根据《深圳证券交易所交易规则》等相关规定，属于股票交易异常波动 的情况。 二、公司关 ...

Revenue and Profit - Revenue for the third quarter was RMB 59.2 million, a decrease of 17.61% year-over-year[5] - Net profit attributable to shareholders was RMB 5.69 million, a slight increase of 0.65% year-over-year[5] - Operating income slightly increased from 205,952,610.25 to 206,044,015.96, a growth of 0.04%[20] - Net profit decreased from 35,774,356.05 to 35,108,623.35, a decline of 1.86%[20] - Net profit attributable to parent company shareholders was RMB 30,491,841.57, a decrease of 2.0% compared to the same period last year[21] - Basic earnings per share were RMB 0.1890, down 2.8% year-over-year[21] - Sales revenue from goods and services was RMB 184,153,951.04, down 11.1% year-over-year[22] Cash Flow - Cash flow from operating activities was negative RMB 17.45 million, a significant decrease of 234.69% year-over-year[5] - Net cash flow from operating activities decreased by 234.69% to -174.50 million yuan, mainly due to the concentrated payment of deferred taxes from 2021 to 2022 and current tax liabilities[10] - Cash flow from operating activities was negative RMB 17,450,234.02, compared to positive RMB 12,955,493.17 in the same period last year[22] - Net cash flow from investing activities increased by 92.90% to -200.62 million yuan, primarily due to increased cash management income compared to the previous year[10] - Cash flow from investing activities was negative RMB 20,062,049.27, an improvement from negative RMB 282,667,719.52 in the same period last year[22] - Net cash flow from financing activities increased by 52.59% to -168.57 million yuan, mainly due to higher shareholder dividends and issuance costs in the previous year[10] - Cash flow from financing activities was negative RMB 16,857,419.14, compared to negative RMB 35,554,742.28 in the same period last year[23] - Total cash and cash equivalents at the end of the period were RMB 93,368,794.97, a decrease of 36.8% from the beginning of the period[23] - Total cash outflow from operating activities was RMB 211,688,325.97, an increase of 3.3% compared to the same period last year[22] - Investment income received was RMB 4,584,326.54, down 15.3% year-over-year[22] - Cash paid for dividends, profits or interest was RMB 16,005,209.00, a decrease of 37.5% compared to the same period last year[23] Assets and Liabilities - Total assets decreased by 2.34% to RMB 837.03 million compared to the end of the previous year[5] - Total assets decreased from 857,063,372.44 to 837,025,177.21, a decline of 2.34%[17] - Current assets decreased from 600,947,533.09 to 491,098,594.06, a decline of 18.28%[17] - Non-current assets increased from 256,115,839.35 to 345,926,583.15, a growth of 35.07%[17] - Total liabilities decreased from 98,392,224.74 to 61,111,219.17, a decline of 37.89%[18] - Current liabilities decreased from 93,355,901.11 to 49,884,616.62, a decline of 46.56%[18] - Non-current liabilities increased from 5,036,323.63 to 11,226,602.55, a growth of 122.91%[18] - Owner's equity increased from 758,671,147.70 to 775,913,958.04, a growth of 2.27%[18] Government Subsidies and Grants - Government subsidies received during the period amounted to RMB 2.78 million for the quarter and RMB 4.39 million year-to-date[6] - Deferred income decreased by 69.73% due to reduced government grants related to assets[9] Receivables and Prepayments - Receivables financing decreased by 36.83% due to reduced bank acceptance bills and timely supplier payments[9] - Prepayments decreased by 49.56% as the company optimized payment methods[9] Intangible Assets and Contract Liabilities - Intangible assets increased by 280.68% due to the company's decision to pay for land use rights from 2003[9] - Contract liabilities decreased by 82.87% due to changes in market demand and logistics efficiency[9] Management Expenses and Credit Impairment - Management expenses increased by 35.28% to 175.94 million yuan, mainly due to increased employee compensation and IT infrastructure investment[10] - Credit impairment losses decreased by 56.62% to 956,744.41 yuan, primarily due to an increase in long-term accounts receivable[10] Subsidiaries and Acquisitions - The company established a wholly-owned subsidiary, Guangdong Zhongou International Pharmaceutical Co., Ltd., with a capital of 10 million yuan to engage in traditional Chinese medicine trade and drug production licensing[14] - The company acquired 100% equity of Huayin International Medical Port Group (Shantou) Co., Ltd. for 0 yuan to integrate business resources and extend the health industry chain[14] Shareholders and Equity - The top shareholder, Guangdong Jinou Health Technology Co., Ltd., holds 45.00% of the shares, totaling 72 million shares[12] - The second-largest shareholder, Hehe Investment Holding (Guangzhou) Partnership Enterprise, holds 11.25% of the shares, totaling 18 million shares[12] - The company's total number of ordinary shareholders at the end of the reporting period was 14,681[12] Operating Costs - Operating costs decreased from 188,766,142.81 to 187,297,045.32, a decline of 0.78%[20]

投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 √其他： 投资者网上集体接待日活动 参与单位名称 及人员姓名 线上参与2023广东辖区上市公司投资者集体接待日活动活动 的投资者 时间 2023 年 9 月 19 日(周二)15:45-17:00 地点 全景网"投资者关系互动平台"（https://ir.p5w.net） 公司接待人员 姓名 董事长、总经理：欧先涛先生 董事、财务总监、董事会秘书：陈秀燕女士 投资者关系活动 主要内容介绍 本次投资者网上集体接待日活动采用网络方式进行，公司参 会人员与投资者进行交流，主要问题及答复如下： 1、国家中成药集采对公司有什么影响？ 答：您好！公司目前没有产品进入中成药集采范围，暂未对公 司经营造成影响，未来公司将紧跟国家步伐，实时关注集采 的相关政策，如有合适机会将会参与集采。 2、本次医药反腐，对公司有影响吗？ 答：您好！公司自成立以来，一直重视经营合规性，通过建立 完善的内部控制和合规体系，加强对关键岗位人员的监督检 查，对关键岗位人员的廉洁守法等方面行为进行规范，始终 | | 严守合规 ...

证券代码：301111 证券简称：粤万年青 公告编号：2023-035 广东万年青制药股份有限公司 关于使用部分闲置募集资金（含超募资金）和自有资金进行 现金管理到期赎回并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司（以下简称"公司"）于 2022 年 12 月 19 日召 开第二届董事会第十次会议及第二届监事会第八次会议，并于 2023 年 1 月 4 日 召开 2023 年第一次临时股东大会，审议通过了《关于使用部分闲置募集资金（含 超募资金）和自有资金进行现金管理的议案》，同意公司在确保不影响正常运营和 募集资金投资项目建设的情况下，使用不超过人民币 2.5 亿元（含 2.5 亿元）的 闲置募集资金（含超募资金）及不超过人民币 2.5 亿元（含 2.5 亿元）的自有资 金进行现金管理，上述额度自股东大会审议通过之日起 12 个月内有效。在上述额 度和期限范围内，资金可循环滚动使用。公司独立董事及保荐机构均发表了明确 同意的意见。具体内容详见公司于 2022 年 12 月 20 日及 2023 年 1 ...

证券代码:301111 证券简称:粤万年青 公告编号:2023-034 1 广东万年青制药股份有限公司 关于参加2023广东辖区上市公司投资者集体接待日活动的公 告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,广东万年青制药股份有限公司(以下简 称"公司")将参加由广东证监局、广东上市公司协会联合举办的"2023 广东辖 区上市公司投资者集体接待日活动",现将有关事项公告如下: 本次投资者集体接待日活动将采取网络远程的方式举行,投资者可以登录 "全景路演"网站(https://rs.p5w.net)参与本次互动交流,活动时间为 2023 年 9 月 19 日(周二)15:45-17:00。 届时,公司董事长、总经理欧先涛先生及董事、财务总监、董事会秘书陈秀燕 女士将通过网络互动形式,与投资者就公司经营情况等方面进行沟通与交流,欢 迎广大投资者踊跃参与。 特此公告。 广东万年青制药股份有限公司 董事会 2023 年 9 月 13 日 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥146,838,141.02, representing a 9.50% increase compared to ¥134,095,511.08 in the same period last year[19]. - The net profit attributable to shareholders decreased by 2.58% to ¥24,805,046.63 from ¥25,462,588.00 year-on-year[19]. - The basic earnings per share decreased by 2.77% to ¥0.1547, down from ¥0.1591 in the same period last year[19]. - The company reported a 10.27% increase in net profit attributable to shareholders after deducting non-recurring gains and losses, reaching ¥16,953,841.62 compared to ¥15,374,644.30 in the previous year[19]. - The total assets at the end of the reporting period were ¥842,902,788.68, a decrease of 1.65% from ¥857,063,372.44 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 1.16% to ¥767,476,217.63 from ¥758,671,171.00 at the end of the previous year[19]. - The company achieved operating revenue of 146.84 million yuan, a year-on-year increase of 9.50%[30]. - The company reported a net profit attributable to the parent company decreased by 2.58% year-on-year, while the net profit after deducting non-recurring gains and losses increased by 10.27% year-on-year, mainly due to a reduction of CNY 2.76 million in government subsidies compared to the same period last year[31]. - The company reported a total comprehensive income for the first half of 2023 was CNY 24,749,394.92, compared to CNY 25,462,588.00 in the first half of 2022[141]. Cash Flow and Investments - The net cash flow from operating activities showed a significant decline of 158.41%, dropping to -¥13,425,326.13 from ¥22,983,043.12 in the previous year[19]. - The cash and cash equivalents decreased to ¥137,668,136.98, representing 16.33% of total assets, down from 20.91% at the end of the previous year[43]. - The total investment amount for the reporting period was ¥128,966,939.10, a significant decrease of 76.90% from ¥558,330,757.88 in the same period last year[47]. - The company reported a total cash outflow from financing activities of 16,502,900.30 CNY, which is a decrease from 35,303,978.19 CNY in the same period last year, indicating a reduction of approximately 53.3%[146]. - The net cash flow from investment activities was -12,147,884.52 CNY, an improvement from -331,662,848.23 CNY in the first half of 2022, showing a reduction in losses by approximately 96.3%[146]. Operational Highlights - Pharmaceutical business revenue was 144.27 million yuan, up 11.90% year-on-year, while mask business revenue declined by 52.14% to 2.46 million yuan[30]. - The sales expense ratio was 41.91%, a decrease of 2.77 percentage points compared to the same period last year[30]. - The company focuses on innovation-driven development, emphasizing traditional Chinese medicine and actively expanding into chemical drugs and medical institution preparations[28]. - The company has established a professional R&D platform for innovative drugs, generic drugs, and improved new drugs, ensuring a strategic guarantee for future product diversification[28]. - The company has a diverse product portfolio with 101 national drug approval products covering 13 applicable disease categories, enhancing its market reach and consumer base[33]. Market and Competitive Environment - The company benefits from supportive national policies aimed at promoting the development of traditional Chinese medicine[27]. - The company is experiencing rising costs for raw materials, particularly traditional Chinese herbs, due to climate and market fluctuations[70]. - Recent industry policies, including two-invoice system and centralized procurement, may impact the company's competitiveness if not addressed effectively[69]. - The company has been recognized for its brand strength, being awarded titles such as "Top 500 Industrial Enterprises in China" and "Top 100 Pharmaceutical Enterprises in China" over its 72-year history[33]. Corporate Governance and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[3]. - The company has not faced any significant environmental penalties and adheres to relevant environmental regulations[80]. - The company has not reported any major environmental pollution incidents during the reporting period[83]. - The company actively engages in investor relations management, ensuring transparency and communication with shareholders[82]. - The company has not reported any significant legal disputes or violations during the reporting period[92]. Future Outlook - Future outlook remains cautious, with emphasis on improving cash flow management and exploring potential market expansion opportunities[146]. - The company plans to maintain its competitive edge by enhancing R&D, optimizing product structure, and expanding sales channels[69]. - The company has extended the expected completion date for the "Traditional Chinese Medicine Production Expansion Project" and "R&D Center Construction Project" to December 31, 2024[59]. Shareholder Information - The total number of shares is 160 million, with 56.16% being limited shares and 43.84% being unrestricted shares[113]. - Guangdong Jinou Health Technology Co., Ltd. holds 45% of the shares, amounting to 72 million shares, with no changes during the reporting period[117]. - The company reported a profit distribution of CNY -25,600,000 for the current period, indicating a loss in profit allocation to shareholders[156]. - The company distributed RMB 16,000,000.00 to shareholders during the reporting period, which is a significant reduction compared to the previous distribution of RMB 25,600,000.00[158]. Accounting and Financial Reporting - The financial report for the first half of 2023 has not been audited, which may affect the reliability of the financial data presented[129]. - The company adheres to the accounting standards and ensures that the financial statements accurately reflect its financial position and operating results[170]. - The company has established specific accounting policies for bad debt provisions, inventory valuation, depreciation of fixed assets, and revenue recognition[169]. - The company confirms its ability to continue as a going concern for at least 12 months from the reporting date[168].

作为广东万年青制药股份有限公司（以下简称"公司"）的独立董事，我们 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《公司章程》及《独立董事工作细则》等相关 规定，本着实事求是、审慎勤勉的原则，认真审阅了公司第二届董事会第十四次 会议的相关资料，并就相关事项发表独立意见如下： 一、关于公司 2023 年半年度募集资金存放与使用情况的独立意见 经核查，公司 2023 年半年度募集资金的存放与使用符合中国证监会、深圳 证券交易所关于上市公司募集资金存放和使用的相关规定，符合公司《募集资金 管理制度》的有关规定，不存在变相改变募集资金投向、损害股东利益的情形。 公司《2023 年半年度募集资金存放与实际使用情况的专项报告》内容真实、准 确、完整，不存在虚假记录、误导性陈述和重大遗漏。 广东万年青制药股份有限公司独立董事 关于第二届董事会第十四次会议相关事项的 独立意见 二、关于公司 2023 年上半年关联方资金占用和对外担保情况的独立意见 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》的相关规定要求，我们对 2023 年上 ...

| 非经营性资金占用 | 资金占用方名称 | 占用方与上 市公司的关 | 上市公司核 算的会计科 | 2023 年期初占 用资金余额 | 2023 | 年上半年占用累计 发生金额（不含利息） | | 2023 年上半年占用 资金的利息（如有） | 2023 年上半年 偿还累计发生金 | 2023 年上半年 期末占用资金余 | 占用形成 原因 | 占用性 质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 联关系 | 目 | | | | | | 额 | 额 | | | | 现大股东及其附属企业 | | | | | | | | | | | | | | 小计 | | | | | | | | | | | | | | 前大股东及其附属企业 | | | | | | | | | | | | | | 小计 | | | | | | | | | | | | | | 总计 | | | | | | | | | | | | | | | | 往来方与上 | 上市公司核 | 2023 年期初往 | 2023 | ...

证券代码：301111 证券简称：粤万年青 公告编号：2023-028 广东万年青制药股份有限公司 第二届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 广东万年青制药股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日在 公司会议室以现场和通讯表决的方式召开公司第二届董事会第十四次会议，此前 公司于 2023 年 8 月 14 日及 2023 年 8 月 16 日以电子邮件形式向全体董事发出会 议通知和补充通知。会议由公司董事长欧先涛先生召集并主持，本次会议应出席 的董事 7 名，实际出席的董事 7 名（其中董事欧泽庆先生、独立董事杨农先生、 朱仁宏先生、苏旭东先生以通讯方式出席并行使表决权）。公司监事、高级管理 人员列席了本次会议。 本次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中 华人民共和国证券法》等法律、法规及《公司章程》等相关规定。 二、董事会会议审议情况 （一）审议通过了《关于公司 2023 年半年度报告及其摘要的议案》 具体内容详见公司同日披露于巨潮资讯网（ ...